Previous Article | Next Article ![]()
Journal of Virology, September 2003, p. 9613-9621, Vol. 77, No. 17
0022-538X/03/$08.00+0 DOI: 10.1128/JVI.77.17.9613-9621.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
and Sandra K. Weller*
Department of Microbiology, University of Connecticut Heath Center, Farmington, Connecticut 06030
Received 3 March 2003/ Accepted 3 June 2003
|
|
|---|
|
|
|---|
Newcomb et al. recently reported that the HSV-1 UL6 protein localizes to a unique vertex on procapsids and forms a 12-member ring in vitro (24); these results suggest that UL6 forms a unique portal through which the viral DNA enters the capsid. After packaging, UL25 may play a role in stabilizing DNA inside the capsid (22, 31). UL17 and UL32 may act to transport capsids to replication compartments (RCs) that are believed to be the sites of cleavage and packaging (20, 32). UL15 and UL28 are believed to comprise two subunits of the terminase (2, 5, 36). The function of UL33 is unknown (3), but it has recently been reported to associate with UL28 and UL15 (7).
By analogy with phage, the terminase complex would be expected to bind viral DNA, transiently associate with the capsids at a unique portal vertex, carry out site specific cleavage of viral DNA, and translocate the DNA inside the capsids in an ATP-dependent fashion. Several lines of evidence support the notion that UL15 and UL28 make up two subunits of the terminase. Protein sequence analysis reveals homology between UL15 and gp17 (a subunit of the T4 terminase), including the Walker A and B boxes characteristic of ATP-binding domains (14, 23). A point mutation in the Walker A box in the HSV-1 UL15 gene prevents cleavage and packaging, suggesting that ATP hydrolysis is required for the process (36). In vitro experiments indicate that UL28 and its homolog in human cytomegalovirus (HCMV) bind to a packaging (pac) site, which is believed to comprise part of the cleavage recognition sequence (2, 9). Furthermore, UL15 and UL28 transiently associate with capsid intermediates (27, 29, 37) and associate with each other as determined by coimmunoprecipitation and copurification (1, 18). Under certain experimental conditions, UL28 requires the presence of UL15 to be transported to the nucleus (1, 18). Mutations in UL15 and UL28 homologues from HCMV have been shown to promote resistance to the same antiviral compounds (11, 15, 19), indicating a possible interaction between the two proteins. Taken together, these lines of evidence suggest UL15 and UL28 may comprise two subunits of the putative terminase.
We used sequence analysis and site-directed mutagenesis here to provide additional evidence that UL15 is part of the terminase complex and to elucidate regions of UL15 that are essential in the cleavage and packaging process. The homology alignments reveal regions that are highly conserved among UL15 homologues in the herpesvirus family and bacteriophage terminases. It seems likely that such evolutionarily conserved regions will be important for biological function. Mutations in exon I of the UL15 gene were engineered in highly conserved regions and then analyzed for biological activities exhibited by the wild-type UL15 protein, including (i) the ability to localize to RCs, (ii) participation in cleavage and packaging, and (iii) transient association with capsid intermediates.
|
|
|---|
Alignments. Using the HSV-1 UL15 protein sequence, a PSI-BLAST search of the NCBI database was performed to identify possible homologues (4). The eight human herpes UL15 homologues were aligned using CLUSTALW (Blosum algorithm) within MacVector (33). Using the lambda family bacteriophage (HK97) gp2 (terminase subunit) protein sequence, a PSI-BLAST search of the NCBI database was performed to identify homologues from other bacteriophage and the herpesvirus family (4). Homologues gp2 (HK97), UL15 (HSV-1), gp17 (kvp40), and gp17 (T4) and the consensus sequence from the above alignment were aligned using CLUSTALW (identity algorithm) within MacVector (33).
Sequential PCR mutagenesis. The G263A mutation in plasmid pcDNAUL15C (containing a CMV promoter and the genomic UL15 sequences, including exon I, UL16, UL17, and exon II) has been previously reported (36). In the present study, four new point mutations were introduced into the UL15 gene. For mutagenesis, pUC119-UL15GE1 plasmid, containing exon I of UL15, was used as the template for two-step PCR with the oligonucleotides listed in Table 1. In each case, the primers were designed to introduce a silent mutation resulting in the introduction of a new restriction enzyme site. The PCR products were subcloned into pUC119-UL15GE1, replacing the existing wild-type UL15 sequences. These mutant clones were confirmed by sequence analysis and detection of the new restriction site within the plasmid. Subsequently, exon I from the pUC119-UL15GE1 mutant plasmids was subcloned into pcDNA-UL15C, replacing the wild-type exon I. The pcDNA-UL15C mutant plasmids were used for transient-transfection and transient-complementation assays, and the pUC119-UL15GE1 plasmids were used for marker transfer.
|
View this table: [in a new window] |
TABLE 1. Primers used in two-step PCRa
|
Construction of UL15 mutants by marker transfer. Marker transfer experiments were carried out as described previously (16). Vero cells were transfected with pUC119-UL15GE1 plasmids and infectious hr81-1 DNA (containing a lacZ insertion in exon I of the UL15 gene). Plaques were stained with neutral red in the presence of the chromogenic substrate X-Gal (5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside); white plaques were purified three times on C2 cells before viral stocks were prepared. Recovery of the desired mutant was verified by Southern blot analysis to detect the introduction of new restriction sites within the viral genome.
Preparation of cell extracts. Vero cells, infected with KOS or UL15 mutant viruses at an MOI of 10 PFU/cell, were harvested and prepared for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis as previously described (35), except that samples were sonicated prior to boiling.
Capsid preparation. Capsid preparation was essentially as previously described (29) except that six large (225-cm2) flasks of MV cells were infected at an MOI of 5 PFU/cell for each virus. Sucrose gradients (20 to 50%) were prepared with a Gradient Master (Biocomp). Sucrose gradient fractions were collected with a piston gradient fractionator (Biocomp). After fraction collection, the samples were precipitated with trichloroacetic acid, and the pellets were washed with ethanol and then resuspended in loading buffer (200 mM Tris [pH 8.8], 1% [vol/vol] 2-mercaptoethanol, 2% [wt/vol] SDS, 10% [vol/vol] glycerol, 0.001% [wt/vol] bromphenol blue). The samples were boiled for 5 min and stored at -20°C.
Western blot analysis.
Samples (10 to 30 µl) were subjected to SDS-PAGE on 10 or 12% polyacrylamide gels and transferred to enhanced chemiluminescence (ECL) membranes. To detect UL15 gene products,
AS9 rabbit polyclonal antibody (generously provided by Daniel Tenney at Bristol-Myers Squibb), was used at a 1:2,000 dilution in TBST (10 mM Tris [pH 8.0], 150 mM NaCl, 0.05% Tween) overnight at 4°C (35). To detect VP5 gene products,
-HSV MCP ICP5 monoclonal antibody (ABI, Columbia, Md.) was used at a dilution of 1:2,000 in TBST overnight at 4°C. Membranes were developed either by ECL (Amersham) or by using alkaline phosphatase (AP; Promega or Bio-Rad) as instructed by the manufacturer.
DNA isolation and Southern blot hybridization. Vero cells (1.5 x 106) were infected at an MOI of 10 PFU/cell for 18 h and harvested, and the total DNA was isolated, as described previously (21, 28). DNA was then digested with BamHI and subjected to electrophoresis and Southern blot analysis (35). Membranes were probed with a 32P-labeled BamHI SQ junction fragment (21).
Immunofluorescence and imaging.
Immunofluorescence was carried out as described by Burkham et al. (12), except as noted. Cells were fixed in 1.5% formaldehyde in phosphate-buffered saline (PBS) for 15 min and permeabilized in cold acetone at -20°C for 2 min. The primary antibodies were applied for 3 h; 39S, a monoclonal antibody (ICP8) (30), was used in 3% normal goat serum (NGS) in PBS (1:200) to detect RCs, and
AS9, a polyclonal antibody in 3% NGS in PBS (1:150), was used to detect UL15. Secondary antibodies, i.e., fluorescein isothiocyanate-conjugated goat anti-mouse and Texas red-conjugated goat anti-rabbit in 3% NGS in PBS (1:200), were applied for 1 h. Images were arranged and labeled by using Adobe Photoshop 5.0 and Illustrator 7.0.
|
|
|---|
![]() View larger version (124K): [in a new window] |
FIG. 1. UL15 homology alignments: UL15 is highly conserved among the herpesvirus family. A PSI-BLAST search was performed on the HSV-1 UL15 protein sequence to obtain all its homologues. The eight human herpesvirus homologues were aligned using CLUSTALW (Blosum algorithm) within MacVector. We assigned 20 CRs between UL15 and its homologues based on the fact that many but not all of these regions are also conserved in bacteriophage terminase proteins (see Fig. 2). The Walker A and B boxes of the putative ATP-binding domain are indicated.
|
![]() View larger version (69K): [in a new window] |
FIG. 2. UL15 and phage alignments. A PSI-BLAST search was performed on gp2 from HK97. UL15 (HSV-1), the UL15 consensus sequence from Fig. 1 [UL15(con)], gp2 (HK97), gp17v (KVP40), and gp17 (T4) were aligned by using CLUSTALW (identity algorithm) within MacVector. Of the 20 CRs shown in Fig. 1, 12 are also conserved between HSV and the phage terminases. The numbers above each CR correspond to the CRs shown in Fig. 1.
|
|
View this table: [in a new window] |
TABLE 2. Designed point mutations in the UL15 proteina
|
![]() View larger version (54K): [in a new window] |
FIG. 3. UL15 detected by Western blot analysis. (A) Western blot analysis of transiently transfected cells. Vero cells (2.1 x 106) transfected with a pcDNA plasmid containing a wild-type or mutant version of the UL15 gene were harvested 20 h posttransfection, subjected to SDS-PAGE on a 12% gel, and transferred to an ECL membrane. Western blot analysis was performed by using UL15 (1:2,000) and AP Immunestar development (Bio-Rad). The arrowhead indicates the band corresponding to the 81-kDa UL15 protein (lane 1). (B and C) Western blot analysis of infected cell lysates. Vero cells (2.1 x 106) were infected with wild-type or mutant virus at an MOI of 10 PFU/cell and harvested 20 h postinfection. The samples were subjected to SDS-PAGE on a 12% gel and then transferred to an ECL membrane. Western blot analysis was performed by using VP5 (1:2,000) and ECL development (Amersham Pharmacia) (B) and UL15 (1:2,000) and AP development (Promega) (C). In panel B, the arrowhead indicates the position of VP5. In panel C, the arrowhead indicates the position of the 81-kDa form of UL15. An extract from insect cells infected with a UL15 expressing baculovirus was used as a control for the presence of the 81-kDa form of UL15 (lane 9). The positions of molecular mass markers (in kilodaltons) are shown in lane 1.
|
|
View this table: [in a new window] |
TABLE 3. Transient-complementation assaya
|
|
View this table: [in a new window] |
TABLE 4. Virus growth assaya
|
Cleavage but not DNA synthesis was inhibited by UL15 mutants. Previously, it has been shown that UL15-null viruses are able to produce viral DNA but not able to carry out cleavage and packaging (25, 35). To determine whether viruses bearing point mutations were also impaired in DNA cleavage, Vero cells (1.5 x 106) were infected with wild-type and mutant viruses at an MOI of 10 PFU/cell. Total DNA was isolated and subjected to Southern blot analysis, as described in Materials and Methods. The cleavage of the viral DNA was detected by the presence of S and Q fragments (Fig. 4A). All viruses were able to produce viral DNA as assessed by the presence of the joint SQ fragments. On the other hand, however, S and Q fragments were only observed in DNA harvested from cells infected with wild-type and mutant Q251E viruses (Fig. 4B, lanes 1 and 4). This indicates that genomic cleavage does not occur in cells infected with the remaining mutant viruses (L120N, Q205E, G263A, Y285S, and hr81-1) (Fig. 4B, lanes 2, 3, 5, 6, and 7, respectively).
![]() View larger version (69K): [in a new window] |
FIG. 4. Southern blot analysis of viral DNA from cells infected with wild-type and mutant viruses. (A) The HSV-1 genome consists of two unique regions, UL and US, which are flanked by repeated sequences a, b, and c. The subscript n in "an" indicates multiple copies of the a sequence. The BamHI fragments corresponding to S, Q, and SQ junction fragments are indicated. (B) Vero cells (107) were infected with the indicated virus at an MOI of 10 PFU/cell for 18 h. Total DNA was digested with BamHI, subjected to electrophoresis, and transferred to a GeneScreen Plus membrane. The membrane was probed with a 32P-labeled BamHI SQ junction fragment. Arrows indicate the junction fragments SQ, Q, and S (from top to bottom). DNA from cells infected with wild-type and null mutant virus (hr81-1) are shown in lanes 1 and 7, respectively. Lanes 2 to 6 contained DNA from cells infected with mutants L120N, Q205E, Q251E, G263A, and Y285S, respectively. Although mutants L120N, Q205E, and hr81-1 appear to contain a reduced amount of SQ DNA compared to wild type and the other mutants, this difference was not reproducible, and we do not feel that it reflects a true reduction in levels of viral DNA synthesis.
|
![]() View larger version (137K): [in a new window] |
FIG. 5. Immunofluorescence analysis. Vero cells were infected with wild-type virus (KOS) (top row), UL15-null virus (hr81-1) (middle row), or the UL15 mutant virus Q205E (bottom row) at an MOI of 10 PFU/cell and fixed for immunofluorescence at 8 h postinfection. Infected cells were stained with anti-ICP8 monoclonal antibody (39S) (left panels, green) and anti-UL15 polyclonal antibody ( AS9) (middle panels, red). The right-hand column labeled Merge shows the merged images. The color was adjusted on the hr81-1 panels to demonstrate the lack of UL15 in these cells.
|
AS9, were previously reported to associate with capsids. The 81-kDa UL15 protein was found to be associated more strongly with B capsids than with C capsids (27, 29, 37). We wanted to examine whether the UL15 point mutations would alter the ability of the 81-kDa UL15 protein to bind to capsids. Western blot analysis with
AS9 (UL15) was performed on capsids isolated from MV cells infected with mutant or wild-type viruses. Capsid bands were purified by sucrose gradient centrifugation and collected with a piston gradient fractionator (Biocomp) as described in Materials and Methods. Figure 6 shows Western blots of sucrose gradient fractions for wild-type (KOS) and mutant viruses. In the top panel for each virus, VP5 was detected, indicating which fractions contained capsids. This was confirmed visually as fraction samples were collected (data not shown). Mutant Q251E was able to produce A, B, and C capsids similar to wild type (Fig. 6). All other mutants produced only B capsids similar to the UL15-null virus (hr81-1). In the bottom panel for each virus, the 81-kDa UL15 protein was detected by use of antibody
AS9 (Fig. 6). The wild-type and Q251E 81-kDa UL15 proteins were found to associate more strongly with B capsids than C capsids. The UL15-null virus, hr81-1, did not produce UL15 protein. UL15 protein produced in cells infected with mutant viruses L120N, Q205E, G263A, and Y285S was also found to associate with B capsids (Fig. 6). This suggests that CRs 1 to 4 are not essential for the association of UL15 protein with B capsids. In summary, it appears that the failure of mutants L120N, Q205E, G263A, and Y285S to cleave and package viral DNA is not due to the inability of UL15 to associate with B capsids.
![]() View larger version (47K): [in a new window] |
FIG. 6. Western blot analysis of wild-type and mutant capsids. MV cells were infected with the indicated virus at an MOI of 5 PFU/cell for 20 h. Sucrose gradient fractions were collected as described in Materials and Methods. Gradient fractions for each virus were subjected to SDS-PAGE on a 10% gel, and Western blot analysis was performed by using AS9 ( UL15) and AP development (Promega) as described in Materials and Methods. The AS9 antibody cross-reacts with VP5 proteins, and this cross-reaction aids in the detection of fractions that contain capsids (top panel for each virus). We previously reported an 87-kDa protein which associated with C capsids that was detected by AS9 (29, 37). In the experimental conditions used in the present study, the 87-kDa protein was not observed. The bottom panel for each virus shows the position of the 81-kDa form of UL15. Fractions containing A, B, and C capsids are marked with brackets.
|
|
|
|---|
By analogy with bacteriophage systems, if UL15 is a component of the terminase, we might expect that it takes part in several functions during encapsidation, including binding and transporting concatemeric DNA to the capsid, docking at the unique portal vertex of the capsid, cleavage and packaging of the viral DNA, and disassociation from the capsid. Direct biochemical analysis of the putative terminase subunits, UL15 and UL28, has been hampered by the insolubility of these proteins expressed in heterologous expression systems. Expression systems tested to date include insect cells infected with recombinant baculoviruses and bacteria transformed with expression vectors (D. Tenney, unpublished data). In addition to the alignment data described above, the strongest evidences to date that UL15 and UL28 are components of the terminase complex are their ability to transiently associate with B capsids during encapsidation (27, 37); the requirement of UL6, the portal protein (24, 27, 37), for the transient association; and the ability of UL28 to bind to pac sequences (2, 9). It was anticipated that the introduction of subtle mutations in CRs of UL15 may result in mutants with a partial phenotype that would be able to carry out some but not all of the functions of the putative terminase. For instance, it might be possible to isolate a mutant that could cleave at the UL terminus but not the US terminus. Such data would support the assignment of UL15 as a component of the terminase.
Several key residues and regions of UL15 were identified that are essential for cleavage and packaging. Mutations in amino acids 120 (CR1), 205 (CR2), 263 (CR3), and 285 (CR4) resulted in the inability to cleave viral DNA, indicating that these residues (and possibly the CRs they are a part of) may be important for this aspect of terminase activity. On the other hand, all mutant UL15 proteins were able to localize to RCs and to associate with B capsids. Thus, the localization to RCs and association with capsids are functions separable from the ability to participate in cleavage and packaging. These point mutations may affect downstream activity such as initiation of packaging, cleavage of the first termini, translocation of the DNA into the capsid, and the ATP hydrolysis necessary for the translocation of the DNA. The mutant G263A (CR3) results in a change in the invariant glycine in the Walker A box of the ATP-binding domain of the UL15 protein. This mutant protein may be defective in the binding and/or hydrolysis of ATP. Another mutation in CR3, Q251E, behaves like wild-type virus, indicating that a conservative change in this CR is tolerated. It is possible that a less conservative change at residue 251 would not be tolerated. Although highly conserved among herpesvirus homologues, amino acid 251 was not conserved among bacteriophage. This may indicate that amino acid 251 is not essential for terminase function per se. Mutant Y285S (CR4) is defective in cleavage and packaging. Interestingly, mutant Y285S protein was detected by immunofluorescence and was found to be associated with capsids but was not readily visible on Western blots of cells infected with mutant virus. The mutation at amino acid 285 may cause the mutant protein to be somewhat unstable in infected cell lysate; however, it may be stabilized by its association with capsids. Alternatively, mutant UL15 may be enriched in the capsid preparation, perhaps by binding better than wild-type UL15 to capsids or by binding irreversibly. It will be of interest to determine whether this mutant exerts a transdominant effect. Because of the apparent instability of the mutant protein in cell extracts, we cannot say whether the defect in cleavage and packaging is a result of the specific mutation in CR4 or due to the relative instability of the protein. The presence of the mutant protein in capsids, however, may indicate the former.
Mutants L120N, Q205E, G263A, and Y285S fail to cleave and package viral DNA despite the fact that they can localize and associate with capsids in a fashion similar to wild type. These results suggest that residues in CRs 1 to 4 are involved in the DNA cleavage reaction. In summary, the mutational analysis described here has resulted in the identification of three separable functions of UL15: localization to RCs, association with capsids, and cleavage of viral DNA. The similarity of the cleavage phenotype in mutants in CRs 1 to 4 indicates that this reaction may be carried out in a synchronized fashion involving multiple regions of the protein.
This work was supported by National Institute of Health grant AI37549.
Present address: Department of Molecular Biology, Princeton University, Princeton, NJ 08544. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»